Understanding the Business of Vaccines

COVID-19

Authors

  • Rajdeepa Maity Research Assistant at O.P. Jindal Global University
  • Rajeev Raman Research Scientist at Leibniz Institute for Neurobiology

DOI:

https://doi.org/10.54945/jjpp.v5i1.147

Keywords:

COVID-19, Vaccine, Open Alliances, Biotech Sector, Pandemic

Abstract

Both the first vaccine produced to combat COVID-19, and the country of its production would not only have the financial edge over other countries, but also geopolitical supremacy. The current statistics of COVID-19 reported around hundreds of thousands of deaths in the world and counting. This article deals with the vaccine development process and costs related to COVID-19 and also highlights the significance of open alliances in the biotech sector in a post-COVID regime. This article focuses on ways in which the challenging worldwide health crises of the current pandemic can be overcome in distinctly local ways through open, transparent, and collaborative practices.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Author Biography

Rajeev Raman, Research Scientist at Leibniz Institute for Neurobiology

Rajeev Raman obtained his PhD from the Centre for Cellular and Molecular Biology (CCMB), Hyderabad, India. In Jan 2016, he joined as a post-doctoral researcher in NPlast group at Leibniz Institute for Neurobiology, Magdeburg, Germany. At present, he is working as Associate Scientist in the same group. His expertise includes protein biochemistry, structure and functions

Downloads

Published

2021-02-01

How to Cite

Maity, R., & Raman, R. (2021). Understanding the Business of Vaccines: COVID-19. Jindal Journal of Public Policy, 5(1), 27–35. https://doi.org/10.54945/jjpp.v5i1.147

Issue

Vol. 5 No. 1 (2021)

Section

Articles
Crossref
Scopus
Google Scholar
Europe PMC

References

Adegbesan, J. A., & Higgins, M. J. 2011. The intra‐alliance division of value created through collaboration. Strategic Management Journal, 32(2):187-211.

Baum, J. A., Calabrese, T., & Silverman, B. S. 2000. Don’t go it alone: Alliance network composition and startups’ performance in Canadian biotechnology. Strategic M anagement J ournal, 21(3): 267-294.

Cojoianu, T., Haney, A., & Meiring, A. 2020. Strategic Alliances as Treatment for COVID-19 and Beyond. Available at SSRN 3616444.

Cohen, W. M., & Levinthal, D. A. 1990. Absorptive capacity: A new perspective on learning and innovation. Administrative Science Quarterly, 128-152.

Diester, L., & Rajagopalan, N. 2012. Are all ‘sharks’ dangerous? New biotechnology ventures and partner selection in R&D alliances. Strategic Management Journal, 33(10): 1115-1134

Dyer, J. H., & Singh, H. 1998. The relational view: Cooperative strategy and sources of interorganizational competitive advantage. Academy of Management Review, 23(4): 660-679.

Ehreth J. 2003. The value of vaccination: A global perspective. Vaccine, 21(27-30) : 4105-4117.

Gouglas, D., Le, T. T., Henderson, K., Kaloudis, A., Danielsen, T., Hammersland, N. C., & Røttingen, J. A. 2018. Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. The Lancet Global Health, 6(12) : 1386-1396

Macher, J. T., &Boerner, C. S. 2006. Experience and scale and scope economies: Trade‐offs and performance in development. Strategic Management Journal, 27(9): 845-865.

Madhok, A., &Osegowitsch, T. 2000. The international biotechnology industry: A dynamic capabilities perspective. Journal of I nternational B usiness S tudies, 31(2), 325-335.

Peeri, N. C., Shrestha, N., Rahman, M. S., Zaki, R., Tan, Z., Bibi, S., & Haque, U. 2020. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?. International Journal of Epidemiology

Plotkin, A. S., Robinson, J. M., Cunningham, G., Iqbal, R. & Larsen, S.M. 2017. The complexity and cost of vaccine manufacturing-An overview. Vaccine, 35 (33): 4064-4071.

Pronker, E. S., Weenen, T. C., Commandeur, H. R., Osterhaus, A. D. M. E.& Claassen, H. J. H. M. 2011. The gold industry standard for risk and cost of drug and vaccine development revisited. Vaccine,29(35): 5846-5849.

Pronker E. S., Weenen, T. C., Commandeur, H., Claassen, E., & Osterhaus, A. 2013. Risk in vaccine research and development quantified. PlosOne,8(3): e57755.

Rothaermel, F. T., & Deeds, D. L. 2004. Exploration and exploitation alliances in biotechnology: A system of new product development. Strategic Management Journal, 25(3): 201-221.

Rothaermel, F. T., & Deeds, D. L. 2006. Alliance type, alliance experience and alliance management capability in high-technology ventures. Journal of Business Venturing, 21(4): 429-460.